10x Genomics, Inc. (TXG) |
| 20.92 0.4 (1.95%) 01-14 13:16 |
| Open: | 20.44 |
| High: | 20.95 |
| Low: | 20.0341 |
| Volume: | 720,418 |
| Market Cap: | 2,581(M) |
| PE Ratio: | -33.21 |
| Exchange: | NASDAQ Global Select |
| Industry: | Medical - Healthcare Information Services |
| Sector: | Healthcare |
| Technical analysis | ||||
![]() |
||||
| sell | buy | |||
| Resistance 2: | 24.74 |
| Resistance 1: | 21.18 |
| Pivot price: | 18.23 |
| Support 1: | 17.47 |
| Support 2: | 15.18 |
| 52w High: | 21.18 |
| 52w Low: | 6.78 |
10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in North America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium and chromium connect instruments, microfluidic chips, slides, reagents, and other consumables products. Its single cell solutions runs on its chromium instruments, which include single cell gene expression for measuring gene activity on a cell-by-cell basis; single cell immune profiling for measuring the activity of immune cells and their targets; single cell Assay for Transposase Accessible Chromati (ATAC) for measuring epigenetics comprising the physical organization of DNA; and single cell multiome ATAC + gene expression for measuring the genetic activity and epigenetic programming in the same cells across tens of thousands of cells in a single experiment. The company also provides visium spatial gene expression solution for measuring spatial gene expression patterns across a single tissue sample or gene expression and protein co-detection when combined with immunofluorescence. It serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.
| EPS | -0.630 |
| Book Value | 6.200 |
| PEG Ratio | 0.00 |
| Gross Profit | 3.799 |
| Profit Margin (%) | -11.89 |
| Operating Margin (%) | -21.17 |
| Return on Assets (ttm) | -8.4 |
| Return on Equity (ttm) | -10.1 |
Tue, 13 Jan 2026
Weak Instrument Sales And No 2026 Outlook Could Be A Game Changer For 10x Genomics (TXG) - Yahoo Finance
Mon, 12 Jan 2026
Why 10x Genomics (TXG) Shares Are Falling Today - Finviz
Mon, 12 Jan 2026
10x Genomics to Advance Research in Diagnostic Applications of Tumor Single Cell and Spatial Profiling - Finviz
Mon, 12 Jan 2026
New study tracks blood signals to guide care for autoimmune disease patients - Stock Titan
Mon, 12 Jan 2026
New AI cancer project will map 500 million immune cells for research - Stock Titan
Mon, 12 Jan 2026
10x Genomics (TXG) Sees Modest Q4 Growth Amid Revenue Challenges - GuruFocus
|
StockChart iOS |
StoxlineLite iOS |
StoxlineLite iOS |
OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |